Assessing the combined effects of Black Cohosh, Soy Isoflavones, and SDG Lignans on menopausal symptoms: a randomized, double-blind, placebo-controlled clinical trial
- PMID: 40131516
- DOI: 10.1007/s00394-025-03588-y
Assessing the combined effects of Black Cohosh, Soy Isoflavones, and SDG Lignans on menopausal symptoms: a randomized, double-blind, placebo-controlled clinical trial
Abstract
Objective: This randomized, double-blind, parallel-group clinical trial aimed to evaluate the efficacy of Black Cohosh, Soy Isoflavones, and SDG Lignans in alleviating menopausal symptoms compared to a placebo.
Methods: Ninety-six postmenopausal women aged 45-60 years were enrolled. Participants were randomized to receive either the study supplements or a placebo for 90 days, with Menopause Rating Scale (MRS) scores collected at baseline and every 4 weeks to monitor symptom changes. Secondary outcomes assessed included hormonal variations and the incidence of adverse symptoms.
Results: Of the initial cohort, 90 participants completed the study with high adherence. Significant improvements were observed in the treatment group across all MRS domains: somatic (- 54.3% difference, p < 0.01), psychological (- 54.3% difference, p < 0.01), urogenital (-37.3% difference, p < 0.01), and total score (- 48.0% difference, p < 0.01). Hormonal changes were modest yet statistically significant for FSH (- 6.7% difference, p < 0.01) and estradiol (12.6% difference, p < 0.01). Adverse events were minimal, transient, and did not require cessation of supplementation.
Conclusion: Black Cohosh, Soy Isoflavones, and SDG Lignans significantly reduced menopausal symptoms with a favorable safety profile. These findings support the potential of this supplement combination as a therapeutic option for menopausal symptom management.
Trial registration: ClinicalTrials.gov NCT06328348.
Keywords: Black Cohosh; Menopause; Menopause Rating Scale; SDG Lignans; Soy Isoflavones.
© 2025. Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: Authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Institutional review board statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Center for New Medical Technologies Ethics Committee (approval number 0162CS_2023, 1 Aug 2023). Informed consent statement: Informed consent was obtained from all subjects involved in the study.
References
-
- Gold EB (2011) The timing of the age at which natural menopause occurs. Obstetr Gynecol Clin 38:425–440 - DOI
-
- Thurston RC, Joffe H (2011) Vasomotor symptoms and menopause: findings from the study of women’s health across the nation. Obstetr Gynecol Clin 38:489–501 - DOI
-
- Panay N (2007) Menopause and the postmenopausal women. In: Edmonds DK (ed) Dewhurst’s Textbook of Obstetrics and Gynaecology, 7th edn. Blackwell Publishing, Oxford, pp 479–492
-
- Bansal R, Aggarwal N (2019) Menopausal hot flashes: a concise review. J Mid Life Health 10:6–13 - DOI
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
